CEL-SCI CORP. NEW DL-01
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more
CEL-SCI CORP. NEW DL-01 (LSRM) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CEL-SCI CORP. NEW DL-01 (LSRM) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CEL-SCI CORP. NEW DL-01 - Net Assets Trend (None–None)
This chart illustrates how CEL-SCI CORP. NEW DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CEL-SCI CORP. NEW DL-01 (None–None)
The table below shows the annual net assets of CEL-SCI CORP. NEW DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CEL-SCI CORP. NEW DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CEL-SCI CORP. NEW DL-01 Competitors by Market Cap
The table below lists competitors of CEL-SCI CORP. NEW DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vrc Real Estate and Investment JSC
VN:VRC
|
$18.29 Million |
|
Yayla Enerji Uretim Turizm ve
IS:YAYLA
|
$18.29 Million |
|
Seker Finansal Kiralama AS
IS:SEKFK
|
$18.29 Million |
|
Dhunseri Ventures Limited
NSE:DVL
|
$18.29 Million |
|
Toray Textiles (Thailand) Public Company Limited
BK:TTT
|
$18.29 Million |
|
WOOJUNG BIO Inc
KQ:215380
|
$18.28 Million |
|
Studio Mir Co. Ltd.
KQ:408900
|
$18.28 Million |
|
Intrepid Metals Corp.
OTCQB:IMTCF
|
$18.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CEL-SCI CORP. NEW DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CEL-SCI CORP. NEW DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CEL-SCI CORP. NEW DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CEL-SCI CORP. NEW DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CEL-SCI CORP. NEW DL-01 (LSRM) | €- | N/A | N/A | $18.29 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |